Entering the ‘Big Data’ Era in Medicinal Chemistry: Molecular Promiscuity Analysis Revisited

References

• Mayer-Schönberger V, Cukier K. Big data: A Revolution That Will Transform How We Live, Work, And Think. Houghton Mifflin Harcourt, MA, USA (2013).
   Google Scholar
• 3D data management: controlling data volume, velocity, and variety. https://blogs.gartner.com/doug-laney/files/2012/01/ad949–3D-Data-Management-Controlling-Data-Volume-Velocity-and-Variety.pdf.
   Google Scholar
• Gartner. Big data. www.gartner.com/it-glossary/big-data/.
   Google Scholar
• Datafloq. Why the 3Vs are not sufficient to describe big data. https://datafloq.com/read/3vs-sufficient-describe-big-data/166/.
   Google Scholar
• Lynch C. Big data: how do your data grow? Nature 455(7209), 28–29 (2008).
   PubMed Web of Science ®Google Scholar
• Marx V. The big challenges of big data. Nature 498(7453), 255–260 (2013).
   PubMed Web of Science ®Google Scholar
• Al-Lazikani B, Workman P. Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. Future Med. Chem. 8(14), 1711–1716 (2016).
   PubMed Web of Science ®Google Scholar
• Bajorath J, Jenkins J, Overington J, Walters WP. Drug discovery and development in the era of big data. Future Med. Chem. 8(15), 1807–1813 (2016).
   PubMed Web of Science ®Google Scholar
• Hu Y, Bajorath J. Learning from ‘big data’: compounds and targets. Drug Discov. Today 19(4), 357–360 (2014).
   PubMed Web of Science ®Google Scholar
• Lusher SJ, McGuire R, van Schaik RC, Nicholson CD, de Vlieg J. Data-driven medicinal chemistry in the era of big data. Drug Discovery Today 19(7), 859–868 (2014).
   PubMed Web of Science ®Google Scholar
• Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat. Biotechnol. 24(7), 805–815 (2006).
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4(11), 682–690 (2008).
   PubMed Web of Science ®Google Scholar
• Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel. 13(3), 297–309 (2010).
   PubMed Web of Science ®Google Scholar
• Jalencas X, Mestres J. On the origins of drug polypharmacology. Med. Chem. Comm. 4(1), 80–87 (2013).
   Google Scholar
• Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery: miniperspective. J. Med. Chem. 57(19), 7874–7887 (2014).
   PubMed Web of Science ®Google Scholar
• Hu Y, Bajorath J. Compound promiscuity - what can we learn from current data. Drug Discov. Today 18(13–14), 644–650 (2013).
   PubMed Web of Science ®Google Scholar
• McGovern SL, Caselli E, Grigorieff NA. Common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45(8), 1712–1722 (1996).
   Google Scholar
• Shoichet BK. Screening in a spirit haunted world. Drug Discov. Today 11(13–14), 607–615 (2006).
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53(7), 2719–2740 (2010).
   PubMed Web of Science ®Google Scholar
• Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature 513(7519), 481–483 (2014).
   PubMed Web of Science ®Google Scholar
• Hu Y, Bajorath J. Promiscuity profiles of bioactive compounds: potency range and difference distributions and the relation to target numbers and families. Med. Chem. Commun. 4, 1196–1201 (2013).
   Google Scholar
• Schneider G, Neidhart W, Giller T, Schmid G. “Scaffold-hopping” by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. Engl. 38(19), 2894–2896 (1999).
   PubMed Web of Science ®Google Scholar
• Müller G. Medicinal chemistry of target family-directed masterkeys. Drug Discov. Today 8(15), 681–691 (2003).
   PubMed Web of Science ®Google Scholar
• Hu Y, Bajorath J. How promiscuous are pharmaceutically relevant compounds? A data-driven assessment. AAPS J. 15(1), 104–111 (2013).
   PubMed Web of Science ®Google Scholar
• Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 (2012).
   PubMed Web of Science ®Google Scholar
• Gaulton A, Hersey A, Nowotka M et al. The ChEMBL database in 2017. Nucleic Acids Res. 45(D1), D945–D954 (2017).
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiao J, Suzek TO et al. PubChem's BioAssay database. Nucleic Acids Res. 40, D400–D412 (2012).
   PubMed Web of Science ®Google Scholar
• Law V, Knox C, Djoumbou Y et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014).
   PubMed Web of Science ®Google Scholar
• OEChem TK. OpenEye Scientific Software, Inc., NM, USA (2012). www.eyesopen.com/.
   Google Scholar
• Weininger D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 28(1), 31–36 (1988).
   Google Scholar
• UniProt Consortium. The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res. 38, D142–D148 (2010).
   PubMed Web of Science ®Google Scholar
• Kenny PW, Sadowski J. Structure modification in chemical databases. In: Chemoinformatics in Drug Discovery. Oprea TI ( Ed.). Wiley-VCH, Weinheim, Germany, 271–285 (2004).
   Google Scholar
• Hussain J, Rea C. Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets. J. Chem. Inf. Model. 50(3), 339–348 (2010).
   PubMed Web of Science ®Google Scholar
• Hu X, Hu Y, Vogt M, Stumpfe D, Bajorath J. MMP-cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs. J. Chem. Inf. Model. 52(5), 1138–1145 (2012).
   PubMed Web of Science ®Google Scholar
• Sterling T, Irwin JJ. ZINC 15 – ligand discovery for everyone. J. Chem. Inf. Model. 55(11), 2324–2337 (2015).
   PubMed Web of Science ®Google Scholar
• Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev. Clin. Pharmacol. 6(1), 41–47 (2013).
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3(8), 673–683 (2004).
   PubMed Web of Science ®Google Scholar
• Chong CR, Sullivan DJ. New uses for old drugs. Nature 448(7154), 645–646 (2007).
   PubMed Web of Science ®Google Scholar
• Fechner N, Papadatos G, Evans D et al. ChEMBLSpace – a graphical explorer of the chemogenomic space covered by the ChEMBL database. Bioinformatics 29(4), 523–524 (2013).
   PubMed Web of Science ®Google Scholar
• Carrascosa MC, Massaguer OL, Mestres J. PharmaTrek: a semantic web explorer for open innovation in multitarget drug discovery. Mol. Inform. 31(8), 537–541 (2012).
   PubMed Web of Science ®Google Scholar
• Canny SA, Cruz Y, Southern MR, Griffin PR. PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem. Bioinformatics 28(1), 140–141 (2012).
   PubMed Web of Science ®Google Scholar
• Howe EA, de Souza A, Lahr DL et al. BioAssay Research Database (BARD), chemical biology and probe-development enabled by structured metadata and result types. Nucleic Acids Res. 43, D1163–D1170 (2015).
   PubMed Web of Science ®Google Scholar
• von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 39, D1060–D1066 (2011).
   PubMed Web of Science ®Google Scholar
• Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness – the Achilles heel of drug-target networks. Nat. Biotechnol. 26(9), 983–984 (2008).
   PubMed Web of Science ®Google Scholar
• Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol. Biosyst. 5(9), 1051–1057 (2009).
   PubMedGoogle Scholar
• Hu Y, Bajorath J. Monitoring drug promiscuity over time. F1000Research 3, 218 (2014).
   PubMedGoogle Scholar
• Han L, Wang Y, Bryant SH. A survey of across-target bioactivity results of small molecules in PubChem. Bioinformatics 25(17), 2251–2255 (2009).
   PubMed Web of Science ®Google Scholar
• Hu Y, Bajorath J. High-resolution view of compound promiscuity. F1000Research 2, 144 (2013).
   PubMedGoogle Scholar
• Hu Y, Jasial S, Bajorath J. Promiscuity progression of bioactive compounds over time. F1000Research 4, 118 (2015).
   PubMedGoogle Scholar
• Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet. 5(4), 262–275 (2004).
   PubMed Web of Science ®Google Scholar
• Jasial S, Hu Y, Bajorath J. Determining the degree of promiscuity of extensively assayed compounds. PLoS ONE 11(4), e0153873 (2016).
   PubMed Web of Science ®Google Scholar
• Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10(2), 130–137 (2010).
   PubMed Web of Science ®Google Scholar
• Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 53(4), 1413–1437 (2009).
   Web of Science ®Google Scholar
• Hu Y, Furtmann N, Bajorath J. Current compound coverage of the kinome. J. Med. Chem. 58(1), 30–40 (2015).
   PubMed Web of Science ®Google Scholar
• Duffner JL, Clemons PA, Koehler AN. A pipeline for ligand discovery using small-molecule microarrays. Curr. Opin. Chem. Biol. 11(1), 74–82 (2007).
   PubMed Web of Science ®Google Scholar